Company

Minervax

Rocket Ship Rating

Rocket Ship Rating: 91 out of 100

We are developing a life-saving vaccine.

Biotech & therapeutics

Status: Operatingas of 2026-09-17
Business model: B2B
Headquarters: Frederiksberg, Denmark

Open relationship map

Claim, correct or request removal

Record updated 28 September 2026

About

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS)

Funding snapshot

Total raised: $57MSum of rounds, as of 2026-09-17Source (opens in a new tab)
Latest round: Undisclosed2023-10-11

Funding rounds

Round, 2023: 2023-10-11
Round, 2022: 2022-12-15
Series B: $57M2020-12-15, Company stated

Products

Other: AlpN GBS